Akiram Therapeutics
Uppsala
About Akiram Therapeutics
Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, AML (Acute Myeloid Leukemia), lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $6.4M
- Last round: Series Unknown (Nov 2022)
- Website: akiramtherapeutics.se
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/akiram-therapeutics-24579 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.